Qiming Wang

AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or MetastaticNon–Small-Cell Lung Cancer With <i>EGFR</i> Exon 19 Deletion or L858R Mutations

Shun Lü, Xiaorong Dong, Hong Jian et al. · Journal of Clinical Oncology · 2022 · 279 citations · Full text

Medicine, Oncology, Pharmacology +16

Durvalumab after Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer

Ying Cheng, David R. Spigel, Byoung Chul Cho et al. · New England Journal of Medicine · 2024 · 275 citations · Full text

Medicine, Oncology, Pharmacotherapy +16

Toripalimab Plus Chemotherapy for Patients With Treatment-Naive Advanced Non–Small-Cell Lung Cancer: A Multicenter Randomized Phase III Trial (CHOICE-01)

Zhijie Wang, Lin Wu, Baolan Li et al. · Journal of Clinical Oncology · 2022 · 172 citations · Full text

Medicine, Oncology, Pharmacology +17

Phase III KEYNOTE-789 Study of Pemetrexed and Platinum With or Without Pembrolizumab for Tyrosine Kinase Inhibitor‒Resistant, <i>EGFR</i> –Mutant, Metastatic Nonsquamous Non–Small Cell Lung Cancer

James Chih‐Hsin Yang, Dae Ho Lee, Jong‐Seok Lee et al. · Journal of Clinical Oncology · 2024 · 142 citations · Full text

Medicine, Oncology, Pharmacology +14

Benmelstobart, anlotinib and chemotherapy in extensive-stage small-cell lung cancer: a randomized phase 3 trial

Ying Cheng, Jianhua Chen, Wei Zhang et al. · Nature Medicine · 2024 · 121 citations · Full text

Medicine, Oncology, Pharmacology +16